The development of new therapy for neonatal chronic lung disease using mesenchymal stem cells derived from fetal appendages.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461644
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Embryonic/Neonatal medicine
• Research Institution: Kobe University
• Principal Investigator: Mizobuchi Masami 神戸大学, 医学(系)研究科(研究院), 客員准教授 (50643954)
• Co-Investigator(Kenkyū-buntansha): NISHIMURA Noriyuki 神戸大学, 大学院医学研究科, 特命教授 (00322719) ; MORIOKA Ichiro 神戸大学, 大学院医学研究科, 特命教授 (80437467)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 間葉系幹細胞 / 細胞治療 / 新生児慢性肺疾患 / 胎児付属物

Outline of Final Research Achievements

Chronic lung disease (CLD) of prematurity is a common and serious complication in preterm infants. To date, there is no effective treatment for CLD. Perinatal inflammation and regulation of the immune responses have been reported to play a crucial role in the development of CLD. Mesenchymal stem cells (MSCs) are multipotent stromal cells that can differentiate into a variety of cell types, including osteocytes, adipocytes and chondrocytes. Recently, MSCs have been reported to secrete a variety of factors that promote tissue repair and decrease inflammatory and immune reactions.
The objective of study was to develop new therapy for CLD using MSCs isolated from fetal appendages in premature infants. In this study, we successfully established a simple and efficient method isolating MSCs from umbilical cord. Furthermore, to determine the effectiveness of MSCs for CLD, we developed an experimental animal model of intra-tracheal bleomycin-induced lung injury.

Free Research Field

新生児学